Pharmaceutical company Breckenridge Pharmaceutical Inc revealed on Monday the receipt of US Food and Drug Administration final approval for its Abbreviated New Drug Application for Rivastigmine Transdermal System in 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours strengths.
The Rivastigmine Transdermal System in 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours strength is the generic for Exelon Patch by Novartis. Breckenridge plans to launch the product with immediate effect.
Rivastigmine Transdermal System was developed in collaboration with Welding GMBH & Co KG, SK Chemicals Co Ltd and Breckenridge.
For the 12 months ending 30 September 2019, the Exelon Patch and its therapeutic equivalents generated annual sales of USD161m according to industry sales data.
European Commission grants Medivir AB's MIV-818 orphan medicinal product designation
Masimo investigates the accuracy of RRp with the Rad-G Pulse Oximeter in paediatric patients
US FDA approves a new test that detects both flu and COVID-19
Fluxergy and MGB collaborate to assess Fluxergy's Research Use Only COVID-19 testing platform
New Study Highlights Senhwa Biosciences Silmitasertib as Potential COVID-19 Treatment
Liminal BioSciences Launches Collection of Convalescent Plasma from COVID-19 Recovered Donors
US FDA Distributes First Round of SARS-CoV-2 Reference Panel Materials
US FDA says country on target to reach a COVID-19 vaccine by 2020 or early 2021